Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EphB2 siRNA
- Development stage
- Preclinical
- Lead developer
- Kennedy Krieger Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
EphB2 siRNA is a small interfering RNA designed to silence the expression of the EphB2 receptor (Ephrin type-B receptor 2). In the context of glioblastoma multiforme (GBM), EphB2 has been identified as a regulator of the proliferation/migration dichotomy. Research conducted at the Kennedy Krieger Institute and Johns Hopkins University demonstrated that silencing EphB2 using siRNA leads to increased tumor cell proliferation but decreased migration and invasion in glioblastoma-derived stem-like neurospheres. This suggests that while EphB2 promotes invasion, it may also act as an anti-proliferative signal, implying that therapeutic targeting of EphB2 might require combination with anti-proliferative agents for optimal efficacy.
- Other names
- EphB2-siRNAEphB-2-siRNAEphB 2-siRNAsiRNA targeting EphB2
02
Targets
EPHB2 (Ephrin type-B receptor 2)
Beyond the preview
Go deeper on EphB2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EphB2 siRNA.